drugset / Trial / NCT00219596

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

NCT00219596

Phase 3 Completed 240 enrolled Viatris Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension

Timeline

Start
2005-06
Primary completion
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule
Subject Timolol Other / unclassified
Subject Xalacom Unknown 50 ug/ml
Subject Xalacom Unknown 0.5 mg/ml